[breadcrumb_custom]

ProQR Therapeutics N.V (NASDAQ:PRQR): Buy, Sell Or Hold At $2.20?

In last trading session, ProQR Therapeutics N.V (NASDAQ:PRQR) saw 0.48 million shares changing hands with its beta currently measuring 0.21. Company’s recent per share price level of $2.20 trading at $0.1 or 4.76% at ring of the bell on the day assigns it a market valuation of $177.80M. That closing price of PRQR’s stock is at a discount of -75.0% from its 52-week high price of $3.85 and is indicating a premium of 49.55% from its 52-week low price of $1.11. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.2 million shares which gives us an average trading volume of 311.79K if we extend that period to 3-months.

ProQR Therapeutics N.V (NASDAQ:PRQR) trade information

Upright in the green during last session for gaining 4.76%, in the last five days PRQR remained trading in the green while hitting it’s week-highest on Friday, 02/09/24 when the stock touched $2.20 price level, adding 4.35% to its value on the day. ProQR Therapeutics N.V’s shares saw a change of 11.11% in year-to-date performance and have moved 3.29% in past 5-day. ProQR Therapeutics N.V (NASDAQ:PRQR) showed a performance of 11.11% in past 30-days. Number of shares sold short was 0.49 million shares which calculate 2.48 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

ProQR Therapeutics N.V (PRQR) estimates and forecasts

Statistics highlight that ProQR Therapeutics N.V is scoring comparatively higher than the scores of other players of the relevant industry. The company added 43.79% of value to its shares in past 6 months, showing an annual growth rate of 77.08% while that of industry is 15.80. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 105.60% in the current quarter and calculating 25.00% increase in the next quarter. This year revenue growth is estimated to rise 322.60% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $15.88 million for the same. And 4 analysts are in estimates of company making revenue of $3.76 million in the next quarter that will end on Mar 2024. Company posted $881.27k and $735.24k of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 1,702.00% while estimating it to be 411.40% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 13.21% during past 5 years.

PRQR Dividends

ProQR Therapeutics N.V is more likely to be releasing its next quarterly report between March 27 and April 01 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

ProQR Therapeutics N.V (NASDAQ:PRQR)’s Major holders

Insiders are in possession of 19.05% of company’s total shares while institution are holding 39.43 percent of that, with stock having share float percentage of 48.71%. Investors also watch the number of corporate investors in a company very closely, which is 39.43% institutions for ProQR Therapeutics N.V that are currently holding shares of the company. Privium Fund Management B.V. is the top institutional holder at PRQR for having 5.34 million shares of worth $8.66 million. And as of Jun 29, 2023, it was holding 6.61% of the company’s outstanding shares.

The second largest institutional holder is Adage Capital Partners GP L.L.C., which was holding about 3.63 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 4.49% of outstanding shares, having a total worth of $5.87 million.

On the other hand, Delaware Group Equity Fds IV-Delaware Healthcare Fund and Fidelity NASDAQ Composite Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 0.62 million shares of worth $1.0 million or 0.77% of the total outstanding shares. The later fund manager was in possession of 36293.0 shares on May 30, 2023, making its stake of worth around $63149.0 in the company or a holder of 0.04% of company’s stock.

On Key

Related Posts